Investor Overview

NASDAQ: XBIT0.2412.27Data provided by Nasdaq.
Minimum 15 minutes delayed.

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Recent News
02/16/17XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa (HS)Printer Friendly Version
01/17/17XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet OncologyPrinter Friendly Version
12/07/16XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal CancerPrinter Friendly Version

Read more »

Upcoming Events

There are currently no events scheduled.

Read more »